Most active New York Stock Exchange-traded stocks
AP - Mon Sep 15, 5:03PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Mon Sep 15, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Watch for Pfizer to Potentially Pullback After Gaining 1.60% Yesterday
Comtex SmarTrend(R) - Mon Sep 15, 3:46PM CDT
Pfizer (NYSE
Nasdaq Underperforms As Leading Growth Stocks Take Heat
at Investor's Business Daily - Mon Sep 15, 10:49AM CDT
The Dow Jones industrial average and S&P 500 held up well Monday, but the Nasdaq took a hit ahead of Tuesday's start of a two-day Federal Reserve meeting. The Nasdaq slumped 1.1%, weighed down by software and solar names. The Dow edged higher, helped...
Early Glance: Pharmaceuticals companies
AP - Mon Sep 15, 9:37AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Market Maker Surveillance Report. PFE, QCOM, CSCO, MSFT, ORCL, AMD, Highest Net Sell Volume and Negative Price Friction For Friday, September 12th 2014
M2 - Mon Sep 15, 2:59AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4813 companies with "abnormal" market making, 1557 companies with positive Friction Factors and 3492 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Friday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Pfizer Inc (NYSE
Midday Glance: Pharmaceuticals companies
AP - Fri Sep 12, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer (PFE) Approaches New Downside Target of $29.16
Comtex SmarTrend(R) - Fri Sep 12, 11:41AM CDT
Shares of Pfizer (NYSE
Trading Guidelines for J&J, Merck, Pfizer, 8 Other Drug Companies
at The Street - Fri Sep 12, 10:32AM CDT
Here are some numbers to help investors make prudent decisions when allocating cash to 11 big-cap pharmaceutical companies.
Study Results, New Collaboration, Drug Designation, Technical Update, and Completion of Transaction - Research Reports on Gilead, AbbVie, Pfizer, United Therapeutics and Brookdale
PR Newswire - Fri Sep 12, 8:10AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), United Therapeutics Corporation (NASDAQ: UTHR) and Brookdale Senior Living, Inc. (NYSE: BKD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6426-100free.
Global Moderate Psoriasis Therapeutics Pipeline Report 2014 - 17 Companies & 23 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jn2cxm/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Johnson & Johnson - Boehringer Ingelheim GmbH - Amgen Inc. - Eli Lilly and Company - Merck & Co., Inc. - AbGenomics International, Inc. - ApoPharma Inc. - Novartis AG - Pfizer Inc. - OPKO Health, Inc. - Idera Pharmaceuticals, Inc. - Almirall, S.A. - Syntrix Biosystems, Inc. - Vascular Biogenics Ltd. - Hy BioPharma Inc. - GlycoMar Limited - Convoy Therapeutics, Inc. Drug Profiles - brodalumab - ixekizumab - secukinumab - tildrakizumab - LAS-41008 - adalimumab biosimilar - baricitinib - AbGn-168H - VB-201 - lunacalcipol - aminopterin sodium - HBP-347 - orilotimod - BI-655066 - IMO-8400 - PF-04965842 - MOL-4249 - AVX-001 - AMG-811 - guselkumab - AKP-11 - cyclosporine - GLY-2028 For more information visit http://www.researchandmarkets.com/research/jn2cxm/moderate
Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Review 2014 - 17 Companies & 27 Drug Profiles
M2 - Fri Sep 12, 3:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r5vn8b/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Genzyme Corporation - F. Hoffmann-La Roche Ltd. - Isis Pharmaceuticals, Inc. - Pfizer Inc. - Zambon Company S.p.A. - Paratek Pharmaceuticals, Inc. - Cytokinetics, Inc. - Neurotune AG - Trophos SA - Nexgenix Pharmaceuticals, LLC - Genethon - Vybion, Inc. - OrphageniX, Inc. - Retrophin, LLC - Neurodyn Inc. - GMP-Orphan SAS - Cellular Biomedicine Group, Inc. Drug Profiles - olesoxime - ISIS-SMNRx - PF-06687859 - RG-7800 - Gene Therapy to Activate SMN for Spinal Muscular Atrophy - AAV9-SMN Gene Therapy - tirasemtiv - PTK-SMA-2 - NXD-30001 - DNA Oligonucleotides for Spinal Muscular Atrophy - RE-003 - Gene Therapy for Spinal Muscular Atrophy - ND-602 - Antisense Oligonucleotide for Spinal Muscular Atrophy and Myotonic Dystrophy - Motor Neuron Precursor Cells - Small Molecule to Activate SMN Protein for Spinal Muscular Atrophy - Agrin Biologic For SMA - sodium phenylbutyrate - Small Molecules for CNS Disorders - PMO-25 - Synthetic Peptides for Central Nervous System Disorders - BBrm-01 - Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - INT-41 - Antisense Oligonucleotides for Spinal Muscular Atrophy - ZP-037 For more information visit http://www.researchandmarkets.com/research/r5...l_muscular
5 Toxic Stocks to Sell Now
at The Street - Thu Sep 11, 12:50PM CDT
It's time to unload these stocks from your portfolio.
Why I'd Avoid Pfizer Inc. Stock Despite the Dividend
George Budwell, The Motley Fool - Motley Fool - Thu Sep 11, 11:28AM CDT
Dividend stocks tend to be strong performers over the long term due to their ability to harness the awesome power of compounding returns. Even so, investors should always bear in mind that not all dividend stocks are good investments, even when they...